Sustained-release (SR) niacin is a form of vitamin B3 designed to minimize the intense flushing associated with immediate-release versions. It functions as a precursor to NAD+, a vital coenzyme for cellular energy production and DNA repair that declines with age. While historically used to improve cholesterol profiles, its healthspan rationale centers on boosting NAD+ to support mitochondrial function. However, large-scale clinical trials have failed to show a cardiovascular benefit when added to statins, and the SR formulation carries a significant risk of liver toxicity.
Verdict
Risks, particularly liver toxicity, likely outweigh unproven healthspan benefits.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
High
EVIDENCE GRADE
B
MONTHLY COST
$10 - $30
Protocol
- Initiate with a low dose of 250-500 mg once daily, taken with a meal to minimize side effects.
- Slowly titrate dose upwards towards a target of 1000-2000 mg per day, based on tolerance and lab results.
- Regular liver function tests (LFTs) are strongly recommended due to the specific risk of hepatotoxicity with this formulation.
Flags
- Sustained-release formulations carry a significantly higher risk of hepatotoxicity (liver damage) than other forms of niacin.
- Large clinical trials (AIM-HIGH, HPS2-THRIVE) found no reduction in cardiovascular events when added to statin therapy.
- May worsen glycemic control in individuals with diabetes or metabolic syndrome.
- Regular monitoring of liver function tests (e.g., ALT, AST) is essential.
- Contraindicated in patients with active liver disease, peptic ulcer disease, or arterial bleeding.